Congress Adopts New User Fee Program

To fund expanded FDA operations designed to streamline drug development and approval, FDA and industry representatives have negotiated the Prescription Drug User Fee Act III.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-07-02-2002

Using Continuous Processes and Automation to Remove Contamination Risk

Takeda Receives Japanese Regulatory Approval for HYQVIA Subcutaneous Injection for Treating Agammaglobulinemia or Hypogammaglobulinemia

FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products